Recent Updates
Recently added Catalysts
TLPH Positive Sentiment

Talphera to Participate at A.G.P. Virtual Healthcare Conference

Thursday, May 16, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Talphera, Inc. has announced its participation in the A.G.P. Virtual Healthcare Conference on May 21, 2024, during which management will engage in a fireside chat. This event is an opportunity for the company to communicate updates regarding its innovative therapies, including its lead product candidate, Niyad™, which has received Breakthrough Device Designation from the FDA. Talphera specializes in developing therapies for medically supervised settings, with additional products in the pipeline.
Price reaction · baseline $1.215 (2024-05-15 close) · hit after-hours · 1 other TLPH headline(s) in the window, move may be shared
day 0 close
-5.3%
day 1
-11.1%
day 3 · peak
-13.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Talphera management's participation indicates proactive engagement with investors.
  • The company is promoting its innovative therapies, especially with Niyad™ receiving FDA Breakthrough Device Designation.
  • The fireside chat provides a platform for transparent communication about their pipeline.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+222%
120-day peak, hindsight
Typical move
22.4%
average across 2 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
sufentanil
Phase 3 · Moderate-to-severe Acute Pain

Full Press Release Details

SAN MATEO, Calif., May 16, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in a fireside chat at the A.G.P. Virtual Healthcare conference May 21, 2024 at 10:40 a.m. ET.
Presentation Information
Presentation Date: Tuesday, May 21, 2024
Presentation Time: 10:40 am ET
Format: Fireside Chat Webcast link: Click here
About Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the FDA. Talphera is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe. This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.

Frequently Asked Questions

What is the date of Talphera's fireside chat?

Talphera's fireside chat is on May 21, 2024.

What time will the fireside chat begin?

The fireside chat will start at 10:40 a.m. ET.

What is Talphera's lead product candidate?

Talphera's lead product is Niyad™, a formulation of nafamostat.

What designation has Niyad™ received from the FDA?

Niyad™ has received Breakthrough Device Designation status from the FDA.

What therapies does Talphera specialize in?

Talphera specializes in innovative therapies for medically supervised settings.

ShareAdd on Google
Tags: TLPH Viatris Investor Conferences Healthcare Talphera Niyad FDA Breakthrough Device healthcare conference
Last updated: May 16, 2024

Biotech snapshot

Cash runway
$17M liquidity · $1M/mo burn
~13 mo
Low dilution risk
Lead asset
sufentanilPhase 3
Moderate-to-severe Acute Pain →

Catalyst track record

+222%
best trade around TLPH's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for TLPH.

See every catalyst's timing & PoA →